Gene Therapy for Dilated Cardiomyopathy

(UPBEAT Trial)

This trial explores a new gene therapy treatment called AFTX-201 for individuals with dilated cardiomyopathy, a heart condition that impairs the heart's ability to pump blood. The focus is on those with a specific BAG3 gene mutation causing this condition. Researchers aim to determine if a single IV dose of AFTX-201 is safe and can improve heart function. Ideal participants exhibit heart failure symptoms, such as tiredness and shortness of breath, and have been diagnosed with this condition. As a Phase 1/Phase 2 trial, this research seeks to understand how the treatment works in people and measure its effectiveness in an initial, smaller group, offering participants a chance to be among the first to benefit from this innovative therapy.

The trial does not specify if you need to stop taking your current medications, but you cannot have had IV therapy with certain heart failure medications in the 30 days before joining.

Research has shown that AFTX-201 appears safe in early animal studies. In these tests, AFTX-201 improved heart function without causing major side effects. The studies also found the tested doses to be safe, suggesting that AFTX-201 is generally well-tolerated. However, human trials are necessary to confirm these results.¹²³⁴⁵

Researchers are excited about AFTX-201 for dilated cardiomyopathy because it offers a novel approach through gene therapy, which is not part of the current standard treatments like beta-blockers, ACE inhibitors, or implantable devices. Unlike these treatments, which manage symptoms and slow disease progression, AFTX-201 targets the underlying genetic causes of the disease. By delivering a single intravenous dose of gene therapy, AFTX-201 aims to correct or modify the genetic defects directly, potentially offering a more sustainable and long-term solution. This innovative mechanism could transform how dilated cardiomyopathy is managed, with the potential for more effective results.

Research has shown that AFTX-201, the treatment under study in this trial, targets the genetic cause of dilated cardiomyopathy related to a BAG3 gene mutation. It employs a specially designed virus to deliver a healthy version of the BAG3 gene directly to the heart. Early results are promising, demonstrating improvements in heart function by replacing the missing or faulty gene. Although the treatment remains under study, these initial findings suggest AFTX-201 could be effective for individuals with this specific heart condition.²³⁴⁵⁶